Represent

Lobbying
Lobbying by AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY

Lobbying Relationship

Client

AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY

More records

Lobbying firm

AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY

More records

* On January 18, ADLM joined with other healthcare groups in writing to House and Senate appropriators in support of increased funding for federal newborn screening programs in the FY24 budget. *On February 26, ADLM joined with other healthcare groups in writing House and Senate appropriators in support of providing the Agency for Healthcare Research and Quality at least $500 million in the FY25 budget. * On March 18, an ADLM led coalition of more than 40 healthcare groups wrote to House and Senate appropriators requesting $10 million for the Centers for Disease Control and Prevention in the FY25 budget to improve pediatric reference intervals. * On March 22, an ADLM led coalition of more than 25 healthcare groups wrote to House and Senate appropriators seeking an additional $7.2 million in the FY25 budget for CDC to better harmonize clinical laboratory test results. * On March 28, ADLM joined with other healthcare groups in seeking $220 million in the FY25 budget for the National Center for Health Statistics.
* On January 24, ADLM and the American Society for Microbiology wrote to the Centers for Medicare and Medicaid Services requesting that the agency reconsider its decision to recognize a Doctorate in Clincal Laboratory Science as an accepted PhD for high complexity laboratory directors under the CLIA regulations. *On March 18, ADLM met with, and submitted comments to, Office of Management and Budget staff in opposition to the release of the Food and Drug Administration final rule on laboratory developed tests. * On March 21, ADLM submitted testimony to the House Energy and Commerce Committee Subcommittee on Health raising concerns about FDA oversight of LDTs.

Duration: November 1, 2007 to present

General Issues: Budget/Appropriations, Medical/Disease Research/Clinical Labs, Medicare/Medicaid, Health Issues, Taxation/Internal Revenue Code, Government Issues, Science/Technology, Labor Issues/Antitrust/Workplace, Copyright/Patent/Trademark, Small Business, Media (Information/Publishing), Education

Spending: about $2,940,000 (But it's complicated. Here's why.)

Agencies lobbied since 2007: U.S. Senate, House of Representatives, Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB), Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Centers For Disease Control & Prevention (CDC), President of the U.S., Vice President of the U.S., Medicare Payment Advisory Commission (MedPAC), Government Accountability Office (GAO), White House Office, Executive Office of the President (EOP), Health Resources & Services Administration (HRSA), Centers For Medicare and Medicaid Services (CMS), U.S. Senate,, Agency for Health Care Policy & Research, Natl Institutes of Health (NIH), Health & Human Services - Dept of (HHS), Y Y, Y, N Y

Bills mentioned

S.794: Local Coverage Determination Clarification Act of 2017

Sponsor: Johnny Isakson (R-Ga.)

H.R.184: Protect Medical Innovation Act of 2018

Sponsor: Erik Paulsen (R-Minn.)

H.R.849: Protecting Seniors Access to Medicare Act

Sponsor: Phil Roe (R-Tenn.)

S.260: Protecting Seniors' Access to Medicare Act of 2017

Sponsor: John Cornyn (R-Texas)

H.R.6283: Truth in Regulations Act of 2016

Sponsor: Pete Sessions (R-Texas)

S.2700: FDA and NIH Workforce Authorities Modernization Act

Sponsor: Lamar Alexander (R-Tenn.)

S.1625: A bill to require a report on the location of C-130 Modular Airborne...

Sponsor: Steve Daines (R-Mont.)

S.1695: Departments of Labor, Health and Human Services, and Education, and...

Sponsor: Roy Blunt (R-Mo.)

H.R.3020: Departments of Labor, Health and Human Services, and Education, and...

Sponsor: Tom Cole (R-Okla.)

S.2014: Next Generation Researchers Act

Sponsor: Tammy Baldwin (D-Wis.)

H.R.1190: Protecting Seniors' Access to Medicare Act of 2015

Sponsor: Phil Roe (R-Tenn.)

H.R.260: INVEST Act

Sponsor: Barbara Lee (D-Calif.)

S.149: Medical Device Access and Innovation Protection Act

Sponsor: Orrin G. Hatch (R-Utah)

S.141: Protecting Seniors' Access to Medicare Act of 2015

Sponsor: John Cornyn (R-Texas)

H.R.1281: Newborn Screening Saves Lives Reauthorization Act of 2014

Sponsor: Lucille Roybal-Allard (D-Calif.)

S.1417: Newborn Screening Saves Lives Reauthorization Act of 2013

Sponsor: Kay Hagan (D-N.C.)

H.R.4302: Protecting Access to Medicare Act of 2014

Sponsor: Joe Pitts (R-Pa.)

S.1284: Departments of Labor, Health and Human Services, and Education, and...

Sponsor: Tom Harkin (D-Iowa)

H.R.933: Consolidated and Further Continuing Appropriations Act, 2013

Sponsor: Harold Rogers (R-Ky.)

S.2014: GI Education Benefit Fairness Act of 2014

Sponsor: Richard J. Durbin (D-Ill.)

H.R.523: Protect Medical Innovation Act of 2013

Sponsor: Erik Paulsen (R-Minn.)

S.232: Medical Device Access and Innovation Protection Act

Sponsor: Orrin G. Hatch (R-Utah)

H.R.351: Protecting Seniors' Access to Medicare Act of 2013

Sponsor: Phil Roe (R-Tenn.)

S.351: Protecting Seniors' Access to Medicare Act of 2013

Sponsor: John Cornyn (R-Texas)

S.3391: TEST Act

Sponsor: Amy Klobuchar (D-Minn.)

H.R.6118: Taking Essential Steps for Testing Act of 2012

Sponsor: Mike Grimm (R-N.Y.)

H.R.3207: Modernizing Laboratory Test Standards for Patients Act of 2011

Sponsor: Michael C. Burgess (R-Texas)

H.R.5651: Food and Drug Administration Reform Act of 2012

Sponsor: Fred Upton (R-Mich.)

S.2516: Food and Drug Administration Safety and Innovation Act

Sponsor: Tom Harkin (D-Iowa)

H.R.2146: DATA Act

Sponsor: Darrell Issa (R-Calif.)

S.1789: 21st Century Postal Service Act of 2012

Sponsor: Joseph I. Lieberman (I-Conn.)

S.2096: Federal Research Public Access Act of 2012

Sponsor: John Cornyn (R-Texas)

H.R.4004: Federal Research Public Access Act of 2012

Sponsor: Mike Doyle (D-Pa.)

S.1493: Foreign Service Line of Duty Death Gratuity Act of 2011

Sponsor: Barbara A. Mikulski (D-Md.)

H.R.3630: Middle Class Tax Relief and Job Creation Act of 2012

Sponsor: Dave Camp (R-Mich.)

H.R.3203: Novel Device Regulatory Relief Act of 2011

Sponsor: Brian P. Bilbray (R-Calif.)

H.R.4: Comprehensive 1099 Taxpayer Protection and Repayment of Exchange Subsidy...

Sponsor: Dan Lungren (R-Calif.)

H.R.452: Medicare Decisions Accountability Act of 2011

Sponsor: Phil Roe (R-Tenn.)

H.R.556: Preserving Patients' Choices Act

Sponsor: Thaddeus McCotter (R-Mich.)

H.R.5037: Federal Research Public Access Act of 2009

Sponsor: Mike Doyle (D-Pa.)

H.R.3962: Preservation of Access to Care for Medicare Beneficiaries and Pension...

Sponsor: John D. Dingell (D-Mich.)

S.1679: Affordable Health Choices Act

Sponsor: Tom Harkin (D-Iowa)

S.1213: Patient-Centered Outcomes Research Act of 2009

Sponsor: Max Baucus (D-Mont.)

H.R.3200: America's Affordable Health Choices Act of 2009

Sponsor: John D. Dingell (D-Mich.)

H.R.3293: Departments of Labor, Health and Human Services, and Education, and...

Sponsor: David R. Obey (D-Wis.)

S.1: American Recovery and Reinvestment Act of 2009

Sponsor: Harry Reid (D-Nev.)

H.R.1: American Recovery and Reinvestment Act of 2009

Sponsor: David R. Obey (D-Wis.)

H.R.1105: Omnibus Appropriations Act, 2009

Sponsor: David R. Obey (D-Wis.)

S.3408: Comparative Effectiveness Research Act of 2008

Sponsor: Max Baucus (D-Mont.)

S.3118: Preserving Access to Medicare Act of 2008

Sponsor: Charles E. Grassley (R-Iowa)

S.3101: Medicare Improvements for Patients and Providers Act of 2008

Sponsor: Max Baucus (D-Mont.)

H.R.3800: Promoting Health Information Technology Act

Sponsor: Anna G. Eshoo (D-Calif.)

H.R.3043: Departments of Labor, Health and Human Services, and Education, and...

Sponsor: David R. Obey (D-Wis.)

S.1710: Departments of Labor, Health and Human Services, and Education, and...

Sponsor: Tom Harkin (D-Iowa)

S.224: SPEAK Act

Sponsor: Christopher J. Dodd (D-Conn.)

H.R.325: SPEAK Act

Sponsor: Vernon J. Ehlers (R-Mich.)

H.R.1501: Medicare Laboratory Services Access Act of 2007

Sponsor: Phil English (R-Pa.)

S.736: Laboratory Test Improvement Act

Sponsor: Edward M. Kennedy (D-Mass.)

S.976: Genomics and Personalized Medicine Act of 2007

Sponsor: Barack Obama (D-Ill.)

S.358: Genetic Information Nondiscrimination Act of 2007

Sponsor: Olympia J. Snowe (R-Maine)

S.605: Allied Health Reinvestment Act

Sponsor: Maria Cantwell (D-Wash.)

H.R.1634: Newborn Screening Saves Lives Act of 2007

Sponsor: Lucille Roybal-Allard (D-Calif.)

S.634: Newborn Screening Saves Lives Act of 2007

Sponsor: Christopher J. Dodd (D-Conn.)

S.1693: Wired for Health Care Quality Act

Sponsor: Edward M. Kennedy (D-Mass.)

H.R.2184: Enhanced Health Care Value for All Act of 2007

Sponsor: Thomas H. Allen (D-Maine)

H.R.2740: Labor, Health and Human Services, Education, Defense, State, Foreign...

Sponsor: Rosa DeLauro (D-Conn.)

H.R.2507: Newborn Screening Saves Lives Reauthorization Act of 2019

Sponsor: Lucille Roybal-Allard (D-Calif.)

H.R.3584: Laboratory Access for Beneficiaries Act

Sponsor: Scott Peters (D-Calif.)

H.R.3031: To amend title XVIII of the Social Security Act to extend funding for...

Sponsor: Judy Chu (D-Calif.)

S.3512: VITAL Act of 2020

Sponsor: Rand Paul (R-Ky.)

S.3737: Strengthening the Public Health Workforce Act

Sponsor: Tina Smith (D-Minn.)

H.R.482: Newborn Screening Saves Lives Reauthorization Act of 2021

Sponsor: Lucille Roybal-Allard (D-Calif.)

S.350: Newborn Screening Saves Lives Reauthorization Act of 2021

Sponsor: Margaret Hassan (D-N.H.)

H.R.4128: VALID Act of 2021

Sponsor: Diana DeGette (D-Colo.)

S.2209: VALID Act of 2021

Sponsor: Richard M. Burr (R-N.C.)

S.1666: VITAL Act of 2021

Sponsor: Rand Paul (R-Ky.)

S.3534: Tracking Pathogens Act

Sponsor: Tammy Baldwin (D-Wis.)

H.R.8188: Saving Access to Laboratory Services Act

Sponsor: Bill Pascrell Jr. (D-N.J.)

S.4449: Saving Access to Laboratory Services Act

Sponsor: Richard M. Burr (R-N.C.)

S.1000: Saving Access to Laboratory Services Act

Sponsor: Sherrod Brown (D-Ohio)

H.R.2377: Saving Access to Laboratory Services Act

Sponsor: Richard Hudson (R-N.C.)

Show All Mentioned Bills

Lobbyists

Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.

Lobbyist	Covered positions?
Vincent Stine PhD	n/a
Vincent G. Stine PhD	n/a
Robert Christenson PhD	n/a

Disclosures Filed

Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.

1st Quarter, 2024

Q1 Report

In Q1, Association for Diagnostics & Laboratory Medicine (formerly AACC) had in-house lobbyists. The report was filed on April 10. Original Filing: 301547772.xml

Lobbying Issues

* On January 18, ADLM joined with other healthcare groups in writing to House and Senate appropriators in support of increased funding for federal newborn screening programs in the FY24 budget. *On February 26, ADLM joined with other healthcare groups in writing House and Senate appropriators in support of providing the Agency for Healthcare Research and Quality at least $500 million in the FY25 budget. * On March 18, an ADLM led coalition of more than 40 healthcare groups wrote to House and Senate appropriators requesting $10 million for the Centers for Disease Control and Prevention in the FY25 budget to improve pediatric reference intervals. * On March 22, an ADLM led coalition of more than 25 healthcare groups wrote to House and Senate appropriators seeking an additional $7.2 million in the FY25 budget for CDC to better harmonize clinical laboratory test results. * On March 28, ADLM joined with other healthcare groups in seeking $220 million in the FY25 budget for the National Center for Health Statistics.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2023

Q4 Report

In Q4, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on Jan. 18. Original Filing: 301527457.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

On October 31, ADLM (formerly AACC) joined with 89 other organizations in requesting the Food and Drug Administration to extend its comment period for responding to Docket No. FDA-2023-N-2177, Medical Devices: Laboratory Developed Tests (LDTs). On November 1st, ADLM (formerly AACC) joined with other groups in writing to the leadership of the Senate Health Education Labor & Pensions and House Energy and Commerce committees urging that they address oversight of LDTs through the modernization of the CLIA regulations. On December 12th, ADLM (formerly AACC) wrote to the leaders of the Senate Health Education Labor & Pensions and House Energy and Commerce committees urging them to direct the Food and Drug Administration to withdrawal their proposed rule (Docket No. FDA-2023-N-2177, Medical Devices: Laboratory Developed Tests) governing LDTs.

Agencies Lobbied

Type of Issue

3rd Quarter, 2023

Q3 Report

In Q3, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on Oct. 16, 2023. Original Filing: 301501554.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2023

Q2 Report

In Q2, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on July 14, 2023. Original Filing: 301476209.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2023

Q1 Report

In Q1, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on April 11, 2023. Original Filing: 301450325.xml

Lobbying Issues

Joined with other healthcare organizations in writing to the House and Senate Labor HHS Subcommittees in support of providing $100 million for the Public Health Workforce Loan Repayment Program and $50 million to initiate a new Bio-Preparedness Workforce Pilot program in the FY24 Labor, Health and Human Services, Education, and related agencies appropriations bill. Joined with other healthcare organizations in writing to the House and Senate Labor HHS Subcommittees in support of providing $175 million for the Centers for Disease Control and Prevention Advanced Molecular Detection program in the FY24 Labor, Health and Human Services, Education, and related agencies appropriations bill. Joined with other healthcare organizations in writing to the House and Senate Labor HHS Subcommittees in support of providing $11.581 billion for the Centers for Disease Control and Prevention programs in the FY24 Labor, Health and Human Services, Education, and related agencies appropriations bill. Joined with other healthcare organizations in writing to the House and Senate Labor HHS Subcommittees in support of providing $215 million for the National Center for Health Statistics in the FY24 Labor, Health and Human Services, Education, and related agencies appropriations bill. Joined with other healthcare organizations in writing to the House and Senate Labor HHS Subcommittees in support of providing $500 million for the Agency for Healthcare Research and Quality in the FY24 Labor, Health and Human Services, Education, and related agencies appropriations bill. Joined with other healthcare organizations in writing to the House and Senate Labor HHS Subcommittees in support of providing $10 million for the Centers for Disease Control and Prevention to develop better pediatric reference intervals in the FY24 Labor, Health and Human Services, Education, and related agencies appropriations bill.

Agencies Lobbied

Type of Issue

4th Quarter, 2022

Q4 Report

In Q4, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on Jan. 6, 2023. Original Filing: 301425229.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2022

Q3 Report

In Q3, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on Oct. 4, 2022. Original Filing: 301401174.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2022

Q2 Report

In Q2, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on July 14, 2022. Original Filing: 301380204.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2022

Q1 Report

In Q1, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on April 13, 2022. Original Filing: 301345612.xml

Lobbying Issues

* AACC joined with other healthcare groups in urging the Senate Health, Education, Labor, and Pensions (HELP) Committee to support an increase in newborn screening funding in FY22 to $49 million. * AACC joined with other healthcare groups in urging House and Senate leaders to include the Newborn Screening Saves Lives Re-authorization Act in the omnibus budget package. * AACC joined with other healthcare groups in urging the House and Senate Labor, Health, Education and Pensions subcommittees to include $10 million for CDC in the FY23 Labor, HHS, Education and Related Agencies appropriations bill to improve pediatric reference intervals * AACC joined with other healthcare groups in urging the House and Senate Labor, Health, Education and Pensions subcommittees to include $500 in the FY23 Labor, HHS, Education and Related Agencies for the Agency for Healthcare Research and Quality * AACC joined with other healthcare groups in recommending that the House and Senate Labor, HHS, Education & Related Agencies subcommittees provide CDC with an additional $7.2 million to harmonize clinical laboratory test results. *AACC met with CDC personnel to discuss improving pediatric reference intervals and the harmonization of clinical laboratory test results

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2021

Q4 Report

In Q4, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on Jan. 6, 2022. Original Filing: 301320343.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2021

Q3 Report

In Q3, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on Oct. 5, 2021. Original Filing: 301296704.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2021

Q2 Report

In Q2, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on July 15, 2021. Original Filing: 301276801.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2021

Q1 Report

In Q1, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on April 1, 2021. Original Filing: 301250207.xml

Lobbying Issues

On January 27, AACC wrote to the White House Pandemic Board raising issues pertaining to lab supply shortages involving COVID-19 testing and offering assistance. On February 2, AACC submitted a statement to the House Energy and Commerce Committee raising concerns about lab supply shortages pertaining to COVID-19 testing. On February 2, AACC wrote to House and Senate leaders expressing concerns about ongoing shortages of supplies needed to perform COVID-19 testing On February 15, AACC wrote to Rep. Roybal-Allard endorsing H.R482, the Newborn Screening Saves Lives Reauthorization Act On March 8, AACC wrote to Senator Paul endorsing the Verified Innovative Testing in American Laboratories Act On March 15, AACC wrote to Senator Hassan endorsing S.350, the Newborn Screening Saves Lives Reauthorization Act

Agencies Lobbied

Type of Issue

Lobbying Issues

On February 17, AACC and other healthcare groups wrote to members of the House and Senate Labor, HHS, Education & Related Agencies appropriations subcommittees seeking $10 million in FY22 for the CDC Environmental Health Laboratory to improve the quality of pediatric reference intervals. On March 1, AACC joined with the CDC coalition in seeking $10 billion for the CDC in the FY22 budget. On March 8, AACC joined with healthcare groups in seeking $56,883,000 for federal newborn screening programs in FY22. On March 17, AACC joined with other healthcare groups in seeking an additional $7.2 million for the CDC Environmental Health Laboratory in FY22 to harmonize clinical laboratory test results. On March 29, AACC joined with other healthcare groups in seeking $200 million for the National Center for Health Statistics in the FY22 budget.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2020

Q4 Report

In Q4, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on Jan. 8, 2021. Original Filing: 301229380.xml

Lobbying Issues

On October 5, AACC wrote to House and Senate leaders seeking greater federal involvement in the production and distribution of laboratory supplies needed to perform COVID-19 testing. On October 6, AACC wrote to the Vice-President seeking greater federal involvement in the production and distribution of laboratory supplies needed to perform COVID-19 testing. On December 2, AACC joined with other lab groups in writing to President-elect Biden in seeking his help in addressing the shortage of COVID-19 laboratory supplies once he assumes office. On December 8, AACC wrote to President-elect Biden seeking his help in reducing the shortage of lab supplies needed for COVID-19 testing once he assumes office as well recommending that he repeal the Centers for Medicare and Medicaid Services October 15, 2020 decision to cut fees for certain COVID-19 tests by 25% if they are not completed within two days.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

On November 13, AACC wrote to HHS seeking assurance that clinical laboratories would continue to get reimbursed for COVID-19 tests performed without an Emergency Use Authorization from the Food and Drug Administration. HHS ended the FDA requirement, but the CARES Act infers that such authorization is needed for payment. On November 6, AACC wrote to the Centers for Medicare and Medicaid Services opposing an October 15, 2020 decision to cut fees for certain COVID-19 tests that were not completed within two days. On November 24, AACC wrote to the Medicare Payment Advisory Commission to urge the panel to focus its attention on fixing the methodology used to determine laboratory fees on the clinical laboratory fee schedule. In addition, the association opposed suggestions that laboratory payments be subject to competitive bidding.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2020

Q3 Report

In Q3, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on Oct. 19, 2020. Original Filing: 301214246.xml

Lobbying Issues

On July 8, AACC joined with other laboratory groups in writing to Vice-President Pence outlining problems clinical laboratories are encountering in obtaining COVID-19 supplies and requesting access to a list of state coordinators distributing supplies. On July 10, AACC joined with other healthcare groups writing to HHS requesting an extension of the COVID-19 public health emergency. On July 28th, AACC wrote to the White House Coronavirus Task Force requesting greater transparency and coordination of the distribution of laboratory supplies for COVID-19 testing. On September 21st, AACC joined with AMP in writing to HHS in support of its recent decision to require that the FDA use the rulemaking process if it wants to regulate laboratory developed tests.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2020

Q2 Report

In Q2, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on July 8, 2020. Original Filing: 301186063.xml

Lobbying Issues

On April 3rd, AACC joined with other healthcare groups in writing House and Senate leadership in support for additional federal funding to rebuild the public health infrastructure. On April 3rd, AACC joined with other healthcare groups in writing to the Department of Health and Human Services seeking greater access to personal protective equipment. On April 16th, AACC wrote to the White House Coronavirus Task Force requesting greater urgency in addressing COVID-19 testing supply chain issues. On April 30th, AACC wrote to the Food and Drug Administration (FDA) expressing concerns with home collection kits for COVID-19 tests. On May 16th, AACC wrote to the FDA seeking greater transparency regarding Emergency Use Authorization decisions. On May 26th, AACC joined with other healthcare groups in endorsing S.3737, the Strengthening the Public Workforce Act, which would create a loan forgiveness program for individuals willing to work in the public health community. On May 26th, AACC wrote to the Senate leadership seeking the inclusion of various provisions in a future COVID-19 package, including a more integrated testing plan, financial assistance to healthcare providers, a more coordinated system for addressing supply chain issues, rebuilding the public health infrastructure, and additional serological testing. On June 15th, AACC wrote to the White House Coronavirus Task Force urging greater federal involvement in COVID-19 testing supply chain issues. On June 18th, AACC had a conference call with HHS to express its concerns regarding the supply chain issues pertaining to COVID-19 testing. On June 26th, AACC joined with other healthcare groups in writing to Senate leaders seeking the inclusion of S.3737, the Strengthening the Public Workforce Act, in future COVID-19 legislation.

Agencies Lobbied

Type of Issue

1st Quarter, 2020

Q1 Report

In Q1, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on April 8, 2020. Original Filing: 301154543.xml

Lobbying Issues

On February 20, 2020 AACC and 19 other organizations wrote to the leadership of the House and Senate Appropriation Subcommittee for Labor, Health, Education & Related Agencies seeking $7.2 million in fiscal year 2021 for the Centers for Disease Control and Prevention to expand its activities to harmonize clinical laboratory test results. On February 26, 2020 AACC joined 157 other groups in writing to the House and Senate Appropriation Subcommittee for Labor, Health, Education & Related Agencies seeking an allocation of $8.3 billion in fiscal year 2021 for the Centers for Disease Control and Prevention. On February 27, 2020 AACC joined 28 other organizations in writing to the leadership of the House and Senate Appropriation Subcommittee for Labor, Health, Education & Related Agencies seeking $10 million in fiscal year 2021 for the Centers for Disease Control and Prevention to improve pediatric reference intervals. On March 13, 2020 AACC joined with other groups in recommending that the House and Senate Appropriation Subcommittee for Labor, Health, Education & Related Agencies allocate $189 in the fiscal year 2021 budget for the National Center for Health Statistics. On March 30, 2020 AACC joined with other organizations in writing to the House and Senate Appropriations Committees recommending that funding be included in the fiscal 2021 budget to conduct an assessment of the federal response to the COVID-19 pandemic.

Agencies Lobbied

Type of Issue

Lobbying Issues

On February 28, 2020 AACC wrote to the Food and Drug Administration requesting that the agency permit laboratories develop laboratory developed tests to detect COVID-19 without having to obtain an Emergency Use Authorization from the agency. On March 25, 2020 AACC wrote to the Department of Health and Human Services requesting that pathologists and related staff be permitted to work offside during the COVID-19 pandemic under their existing CLIA lab certificate. On March 27, 2020 AACC endorsed S.3512, the Verified Innovative Testing in American Laboratories (VITAL) Act, which would codify federal regulation of laboratory developed tests under the Clinical Laboratory Improvement Amendment regulations overseen by the Centers for Medicare and Medicaid Services.

Agencies Lobbied

Type of Issue

4th Quarter, 2019

Q4 Report

In Q4, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on Jan. 13, 2020. Original Filing: 301104817.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

On December 2, 2019, AACC joined with other members of the healthcare community in writing to the House and Senate in support of H.R.3584, the Laboratory Access for Beneficiaries (LAB) Act, which would delay the reporting of lab financial data for one year and require the Medicare Payment Advisory Committee (MedPAC) to conduced a study on the payment methodology used by the Centers for Medicare Services for reimbursing clinical laboratories. On December 5, 2019, AACC met with House and Senate lawmakers and staff in support of H.R.3584, the LAB Act. On December 11 & 18, 2019, AACC conducted a grassroots campaign targeted towards House and Senate members in support of H.R.3584. On October 3, 2019, AACC conducted a congressional briefing on point of care testing for House and Senate congressional staff. The association urged the congressional offices to request the Department of Health and Human Services Office of the Inspector General to conduct a study on the quality of testing provided by Certificate of Waiver testing sites under the Clinical Laboratory Improvement Amendments and make recommendations for improvement.

Agencies Lobbied

Type of Issue

Lobbying Issues

On December 19, 2019, AACC joined with 60 other organizations in writing to the Department of Health and Human Services to request that the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) resume its scheduled meetings while Congress continued its efforts to reauthorize the Newborn Screening Saves Lives Act. On October 7, 2019, AACC joined other healthcare groups in meeting with the Food and Drug Administration (FDA) to express its concerns with ongoing efforts to expand federal regulation of laboratory developed tests (LDTs). On December 6, 2019, AACC joined other healthcare groups in meeting with House and Senate congressional staff and the FDA to express its concerns regarding draft legislation (the Verifying Accurate, Leading-edge IVCT Development Act) that would expand federal oversight of LDTs.

Agencies Lobbied

Type of Issue

3rd Quarter, 2019

Q3 Report

In Q3, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on Oct. 9, 2019. Original Filing: 301064069.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2019

Q2 Report

In Q2, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on July 9, 2019. Original Filing: 301043748.xml

Lobbying Issues

On June 5, 2019 AACC members met with House and Senate congressional staff in support of providing the Centers for Disease Control and Prevention with an additional $10 million in FY20 for improving the quality of pediatric reference intervals. On June 5, 2019 AACC members met with House congressional staff in support of providing the Centers for Disease Control with an additional $4 million for the harmonization of clinical laboratory test results, which was included in H.R.2740, the Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020. On June 11, 2019 AACC joined with the CDC Coalition in writing to Senators in support for the spending amount of the overall spending level allocated to the Centers for Disease Control and Prevention in H.R.2740, the Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020, which was passed by the House of Representatives.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2019

Q1 Report

In Q1, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on April 10, 2019. Original Filing: 301023968.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2018

Q4 Report

In Q4, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on Jan. 10, 2019. Original Filing: 301003493.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2018

Q3 Report

In Q3, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on Oct. 2, 2018. Original Filing: 300982382.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2018

Amendment

AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY amended a lobbying report for in-house lobbying in Q32018 on Oct. 2, 2018 Original Filing: 300982385.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2018

Q2 Report

In Q2, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on July 12, 2018. Original Filing: 300964250.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2018

Q1 Report

In Q1, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on April 9, 2018. Original Filing: 300942985.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2017

Q4 Report

In Q4, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on Jan. 11, 2018. Original Filing: 300922664.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2017

Q3 Report

In Q3, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on Oct. 17, 2017. Original Filing: 300905369.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2017

Q2 Report

In Q2, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on July 18, 2017. Original Filing: 300886995.xml

Lobbying Issues

AACC joined with other healthcare providers in writing to House and Senate appropriators supporting nearly $50 million in federal funding for the HRSA and CDC newborn screening programs in the FY'18 Labor, HHS, Education and Relation Agencies appropriations bill. AACC joined with the Friends of AHRQ in writing to House and Senate appropriators supporting federal funding for AHRQ in FY'18 Labor, HHS, Education and Relation Agencies appropriations bill consistent with its FY'15 budgetary authority. AACC joined with the March of Dimes and other healthcare groups in writing to House and Senate appropriators opposing proposed Administration cuts in HRSA and CDC newborn screening programs in FY'18. AACC met with House and Senate members and staff urging that $9.2 million be included in the FY'18 Labor, HHS, Education and Relation Agencies appropriations bill to fund CDC efforts to harmonization clinical laboratory test results.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2017

Q1 Report

In Q1, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on April 17, 2017. Original Filing: 300866131.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2016

Q4 Report

In Q4, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on Jan. 4, 2017. Original Filing: 300843618.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2016

Q3 Report

In Q3, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on Oct. 13, 2016. Original Filing: 300827321.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2016

Q2 Report

In Q2, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on July 12, 2016. Original Filing: 300808489.xml

Lobbying Issues

AACC joined with the March of Dimes and other healthcare groups in urging House and Senate leaders to provide emergency supplemental funding to assist federal agencies deal with the Zika virus in the United States. AACC and a number of other healthcare groups wrote to House and Senate appropriators seeking an additional $9.2 million for the Centers for Disease Control and Prevention Environmental Health Laboratory in the fiscal year 2017 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Bill to harmonize clinical laboratory test results. AACC also met with congressional staff to discuss this issue. AACC wrote to House leaders supporting the inclusion of report language in the Labor HHS Education and Related Agencies appropriations bill that directs the FDA to stop work on the laboratory developed test guidance until Congress takes action.

Agencies Lobbied

Type of Issue

Lobbying Issues

AACC contacted Senate leaders in support of an amendment included in S.2700, the FDA and NIH Workforce Authorities Modernization Act, which would require the FDA to explain its rationale for choosing to set policy via guidance rather that the ulemaking process. AACC contacted the Centers for Medicare and Medicaid Services and requested that the agency suspend a provision in Memorandum S&C 16-18-CLIA, which grants equivalency to nursing degrees for the purposes of qualifying nurses as high and moderate complexity healthcare personnel. The Association suggested that such changes should have been considered through the rulemaking process. AACC met with congressional staff in support of maintaining CLIA'88 oversight of laboratory developed tests.

Agencies Lobbied

Type of Issue

1st Quarter, 2016

Q1 Report

In Q1, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on April 11, 2016. Original Filing: 300789444.xml

Lobbying Issues

AACC joined with the Friends of AHRQ in writing legislators in support of increasing funding for AHRQ in the fiscal year 2017 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Bill. AACC joined with the March of Dimes and other healthcare groups in urging House and Senate leaders to provide emergency supplemental funding to assist federal agencies deal with the Zika virus in the United States. AACC and a number of other healthcare groups wrote to House and Senate appropriators seeking an additional $9.2 million for the Centers for Disease Control and Prevention Environmental Health Laboratory in the fiscal year 2017 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Bill to harmonize clinical laboratory test results.

Agencies Lobbied

Type of Issue

4th Quarter, 2015

Q4 Report

In Q4, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on Jan. 13, 2016. Original Filing: 300771312.xml

Lobbying Issues

Harmonization of Clinical Laboratory Tests -- AACC and its representatives met with and educated congressional staff about the need to provide additional federal funding to the Centers for Disease Control and Prevention to harmonize clinical laboratory test results. AACC and its representatives met with and educated congressional staff about its concerns with ongoing efforts to expand Food and Drug Administration oversight to laboratory developed tests. AACC asserted that the existing regulatory structure should be maintained and that the Centers for Medicare and Medicaid Services should remain the primary oversight body of LDTs. Direct-to-Consumer Testing -- AACC and its representatives educated congressional staff about the expanded use of DTC testing and the need for agencies to ensure that testing facilities performing such tests comply with federal quality and marketing practices. In addition, AACC recommended that FDA and CMS establish requirements mandating that DTC providers disclose sufficient information about their products and services to consumers. Precision Medicine - AACC and its representatives educated congressional staff on the value of personalized medicine in improving patient care. AACC recommended that Congress urge government agencies to streamline regulations that hinder the development of this promising field and ensure that such tests are adequately reimbursed.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2015

Q3 Report

In Q3, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on Oct. 15, 2015. Original Filing: 300753857.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2015

Q2 Report

In Q2, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on July 6, 2015. Original Filing: 300731795.xml

Lobbying Issues

AACC contacted House and Senate staff and legislators to express concerns about ongoing efforts to expand Food and Drug Administration oversight to laboratory developed tests. Currently LDTs are regulated by the Centers for Medicare and Medicaid Services. AACC also contacted House and Senate staff and legislators to discuss the harmonization of clinical laboratory test results. The Accompanying Language to the Consolidated and Further Continuing Appropriations Act of 2015 included a recommendation under the Centers for Disease Control Prevention Environmental Health section that encourages CDC to work with the private sector in promoting harmonization. AACC mentioned its intent to develop and circulate a legislative proposal to satisfy that recommendation. AACC also expressed its support for federal efforts to advance personalized medicine with House, Senate and White House personnel.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2015

Amendment

AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY amended a lobbying report for in-house lobbying in Q12015 on April 13, 2015 Original Filing: 300714299.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2015

Q1 Report

In Q1, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on April 2, 2015. Original Filing: 300712341.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2014

Q4 Report

In Q4, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on Jan. 12, 2015. Original Filing: 300694188.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2014

Q3 Report

In Q3, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on Oct. 8, 2014. Original Filing: 300674383.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2014

Q2 Report

In Q2, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on July 17, 2014. Original Filing: 300658740.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2014

Q1 Report

In Q1, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on April 15, 2014. Original Filing: 300635752.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2013

Q4 Report

In Q4, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on Jan. 2, 2014. Original Filing: 300611054.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2013

Amendment

AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY amended a lobbying report for in-house lobbying in Q32013 on Oct. 27, 2014 Original Filing: 300690184.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2013

Amendment

AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY amended a lobbying report for in-house lobbying in Q32013 on Oct. 27, 2014 Original Filing: 300690174.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2013

Q3 Report

In Q3, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on Oct. 10, 2013. Original Filing: 300592071.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2013

Q2 Report

In Q2, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on July 18, 2013. Original Filing: 300575475.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2013

Amendment

AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY amended a lobbying report for in-house lobbying in Q12013 on July 18, 2013 Original Filing: 300575555.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2013

Q1 Report

In Q1, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on April 4, 2013. Original Filing: 300547287.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2012

Q4 Report

In Q4, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on Jan. 14, 2013. Original Filing: 300528395.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2012

Q3 Report

In Q3, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on Oct. 2, 2012. Original Filing: 300503614.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2012

Q2 Report

In Q2, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on July 3, 2012. Original Filing: 300480495.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2012

Q1 Report

In Q1, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on April 9, 2012. Original Filing: 300458306.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2011

Q4 Report

In Q4, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on Jan. 5, 2012. Original Filing: 300434733.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2011

Q3 Report

In Q3, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on Oct. 4, 2011. Original Filing: 300410665.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2011

Q2 Report

In Q2, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on July 7, 2011. Original Filing: 300386559.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2011

Q1 Report

In Q1, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on April 5, 2011. Original Filing: 300360149.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2010

Q4 Report

In Q4, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on Jan. 6, 2011. Original Filing: 300335321.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2010

Q3 Report

In Q3, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on Oct. 5, 2010. Original Filing: 300308821.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2010

Q2 Report

In Q2, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on July 6, 2010. Original Filing: 300282095.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2010

Q1 Report

In Q1, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on April 8, 2010. Original Filing: 300255290.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2009

Q4 Report

In Q4, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on Jan. 6, 2010. Original Filing: 300227653.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2009

Q3 Report

In Q3, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on Oct. 7, 2009. Original Filing: 300201322.xml

Lobbying Issues

S.1213, the Patient-Centered Outcomes Research Act of 2009. AACC wrote legislators expressing support for the measure, which would increase federal funding for comparative effectiveness reseach. S. 1679, the Affordable Health Choices Act, Title II, Improving the Quality and Efficiency of Health Care, Subtitle B, Section 219, Center for Health Outcomes Research and Evaluation, Section 937, Center for Health Outcomes Research and Evaluation. AACC wrote to the Senate Health Education Labor and Pensions Committee and contacted Senate staff to express support for retaining the Agency for Healthcare Research and Quality as the leading federal agency responsible for comparative effectiveness research. S. 1679, the Affordable Health Choices Act, Title II, Improving the Quality and Efficiency of Health Care, Subtitle B, Section 219, Center for Health Outcomes Research and Evaluation, Section 937, Center for Health Outcomes Research and Evaluation. AACC joined with other health care organizations in sending a coalition letter to Senate legislators in support of retaining AHRQ as the leading federal agency responsible for comparative effectiveness research. H.R. 3200, America's Affordable Health Choices Act, Division A, Title IV Quality, Section A Comparative Effectiveness Research Section 1401. AACC joined with other health care organizations in sending a coalition letter to House legislators in support of retaining AHRQ as the leading federal agency responsible for comparative effectiveness research.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2009

Q2 Report

In Q2, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on July 6, 2009. Original Filing: 300172775.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2009

Q1 Report

In Q1, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on April 7, 2009. Original Filing: 300144127.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2008

Q4 Report

In Q4, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on Jan. 5, 2009. Original Filing: 300113411.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2008

Q3 Report

In Q3, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on Oct. 6, 2008. Original Filing: 300088378.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2008

Q2 Report

In Q2, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on July 8, 2008. Original Filing: 300061846.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2008

Q1 Report

In Q1, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on April 8, 2008. Original Filing: 300033331.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

0th Quarter, 2007

MM Report

In MM, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY had in-house lobbyists. The report was filed on Aug. 6, 2007. Original Filing: 200046561.xml

Lobbying Issues

1. H.R.3043, S.1710, Departs. of Labor, Health and Human Services, and Education, and Related Agencies Approp. Act of 2008, Title II, HHS, NIH, Office of the Director. AACC wrote to legislators in support of funding for the NIH National Children's study. 2. H.R.3043, S.1710, Departs. of Labor, Health and Human Services, and Education, and Related Agencies Approp. Act of 2008, Title II, HHS, AHRQ. AACC joined with the Friends of AHRQ coalition in writing in support of increased funding for AHRQ research studies. 3. H.R.3043, S.1710, Departs. of Labor, Health and Human Services, and Education, and Related Agencies Approp. Act of 2008, Title II, HHS, CDC. AACC joined with the Friends of the National Center for Health Statistics coalition in support of increased funding NCHS activities.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

1. AACC endorsed S.358, the Genetic Information Nondiscrimination Act, which would bar health insurers and employers from discriminating against individuals solely on the basis of genetic information. 2. AACC endorsed S.605, the Allied Health Professions Reinvestment Act, which would provide additional federal assistance to reduce the shortage of allied health personnel.3. AACC endorsed H.R.1634 and S.634, the Newborn Screening Saves Lives Act of 2007, which would provide federal funding to expand newborn education and outreach efforts and improve the coordination of follow-up care. 4. AACC joined a Friends of AHRQ coalition letter expressing support for comparative effectiveness research, particularly in regards to maintaining AHRQ's prominent role in this field. 5. AACC endorsed S.1693, the Wired for Health Care Quality Act, which proposes a variety of stimuli to create interactive electronic medical record (EMR) networks that can be used by health care providers to improve patient care. 6. AACC endorsed H.R.2184, the Enhanced Health Care Value for All Act of 2007, which would significantly increase federal funding for comparative effectiveness research.

Agencies Lobbied

Type of Issue

Source: Clerk of the U.S. House of Representatives and Secretary of the Senate

Legislators

Bills

Statements

Lobbying

Travel

Lobbyists

Disclosures Filed